Mackenzie Financial Corp Grifols Sa Transaction History

Mackenzie Financial Corp

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 10, 2021	SELL	$16.86 - $19.67 $7.75 Million - $9.05 Million	-459,911 Closed	0 $0
Q3 2020 Nov 13, 2020	SELL	$15.4 - $20.16 $4.47 Million - $5.85 Million	-290,155 Reduced 38.68%	459,911 $7.98 Million
Q2 2020 Aug 13, 2020	SELL	$18.24 - $21.45 $6.03 Million - $7.09 Million	-330,549 Reduced 30.59%	750,066 $13.7 Million
Q1 2020 May 14, 2020	BUY	$16.28 - $25.63 $553,813 - $871,881	34,018 Added 3.25%	1,080,615 $21.8 Million
Q4 2019 Feb 13, 2020	BUY	$19.57 - $23.52 $3.01 Million - $3.61 Million	153,594 Added 17.2%	1,046,597 $24.4 Million
Q3 2019 Nov 14, 2019	BUY	$19.85 - $22.76 $1.8 Million - $2.06 Million	90,661 Added 11.3%	893,003 $17.9 Million
Q2 2019 Aug 14, 2019	BUY	$17.59 - $21.1 $14.1 Million - $16.9 Million	802,342 New	802,342 $16.9 Million

164

140M

288K

389K

Ticker GRFS
Exchange OTC
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 678,910,976
Market Cap $5.31B
Description
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solut...

Get notified when there are updates to the investment portfolio of Mackenzie Financial Corp, based on Form 13F filings with the SEC.

Stay updated on Mackenzie Financial Corp with notifications on news.